This program is intended for physicians and other healthcare professionals who care for patients with Follicular Lymphoma, including hematologists/oncologists, advanced care practitioners, pharmacists, and nurses.
The goal of this activity is to improve the knowledge, confidence, and competence of HCPs treating patients with relapsed/refractory follicular lymphoma by leveraging recent and emerging data that must be considered in treatment decisions.
Upon completion of this activity, participants should be able to:
Incorporate safety and efficacy data on novel and emerging therapies into management plans for patients with relapsed/refractory follicular lymphoma
Plan the optimal sequence of PI3K inhibitors, epigenetic modifiers, CAR T-cell therapy, and antibodies for patients with relapsed/refractory follicular lymphoma based on available evidence, as well as guideline and expert recommendations
Manage adverse events associated with novel treatment regimens in relapsed/refractory follicular lymphoma
Identify patients with relapsed/refractory follicular lymphoma who are eligible for enrollment on a clinical trial
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:
Ian W. Flinn, MD, PhD: consultant (paid to institution): AbbVie, AstraZeneca, BeiGene, Century Therapeutics, Genentech, Genmab, Hutchison MediPharma, Iksuda, InnoCare Pharma, Janssen, Kite, MorphoSys, Myeloid, Novartis, Nurix, Pharmacyclics, Roche, Secura Bio, Servier, Takeda, TG Therapeutics, Verastem, Vincerx, Xencor; researcher (paid to institution): 2seventy bio, AbbVie, Acerta, Agios, ArQule, AstraZeneca, BeiGene, Biopath, Bristol-Myers Squibb, CALIBR, CALGB, Celgene, City of Hope National Medical Center, Constellation, Curis, CTI Biopharma, Epizyme, Fate, Forma, Forty Seven, Genentech, Gilead Sciences, InnoCare, IGM Biosciences, Incyte, Infinity, Janssen, Kite Pharma, Loxo, Merck, Millennium, MorphoSys, Myeloid, Novartis, Nurix, Pfizer, Pharmacyclics, Portola, Rhizen, Roche, Seattle Genetics, Tessa Therapeutics, TCR2 Therapeutics, TG Therapeutics, Trillium, Triphase Research & Development Corp, Unum Therapeutics, Verastem.
Laurie H. Sehn, MD, MPH: consultant/advisor/speaker: AbbVie, AstraZeneca, Celgene/Bristol-Myers Squibb, Gilead/Kite, Incyte, Janssen, Merck, Roche/Genentech, Seattle Genetics, Teva, TG Therapeutics.
The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.
Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from March 10, 2023, through March 09, 2024:
You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by clicking the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.